Therapeutics News

Healio has compiled April’s most-read news in dermatology.

The use of thermal imaging and the ALT-70 prediction model were helpful in differentiating cellulitis from pseudocellulitis, reducing misdiagnosis, according to a study.

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.

Hepatic adverse events with bimekizumab were low and consistent through 2 years of treatment among patients with moderate to severe psoriasis, according to a study.

ARCA biopharma and Oruka Therapeutics have entered into a definitive merger agreement and will now operate under Oruka Therapeutics, ARCA announced in a press release.

Healio has compiled March’s most-read news in dermatology.

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.

Prescribers have expressed an overall positive opinion toward the off-label use of low-dose oral minoxidil for the treatment of androgenetic alopecia, though opinions varied based on years of experience, according to a study.

SAN DIEGO — Basal cell carcinoma treatment with jet injection of photodynamic therapy was well tolerated by patients in a pilot study, according to a poster presentation at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — In this Healio video perspective here at the American Academy of Dermatology, Brett King, MD, PhD, FAAD, discusses how new Janus kinase inhibitors have changed the paradigm of alopecia areata treatment.